Royal Bank Of Canada Has Lowered Expectations for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its target price decreased by equities researchers at Royal Bank Of Canada to $1.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 116.92% from the company’s previous close.

EYPT has been the topic of a number of other research reports. Jefferies Financial Group lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research note on Monday. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Stifel Nicolaus initiated coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price target on the stock. HC Wainwright restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 27th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Price Performance

Eyepoint Pharmaceuticals stock traded up $0.02 during midday trading on Tuesday, reaching $0.46. The company’s stock had a trading volume of 14,529,600 shares, compared to its average volume of 3,096,903. The stock’s 50-day simple moving average is $4.77 and its 200-day simple moving average is $10.30. Eyepoint Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $19.11. The stock has a market capitalization of $39.74 million, a P/E ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. As a group, equities research analysts expect that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in EYPT. Janus Henderson Group PLC increased its holdings in Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after acquiring an additional 663,439 shares in the last quarter. Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals during the first quarter valued at $36,414,000. Hsbc Holdings PLC purchased a new position in Eyepoint Pharmaceuticals during the first quarter valued at $10,743,000. Stempoint Capital LP grew its position in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after purchasing an additional 456,915 shares during the period. Finally, Principia Wealth Advisory LLC grew its position in shares of Eyepoint Pharmaceuticals by 2.6% in the second quarter. Principia Wealth Advisory LLC now owns 649,944 shares of the company’s stock valued at $9,294,000 after purchasing an additional 16,180 shares during the period. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Some analysts see potential recovery value at the current price. Mizuho maintained its neutral rating while assigning a $0.50 price target, and Jefferies moved to hold with a $1.00 target. These targets imply substantial upside from the current $0.44 level, although both firms remain cautious. TickerReport analyst coverage
• Positive Sentiment: Unusual options activity included the purchase of 7,885 call contracts, about 69% above typical daily volume, suggesting some traders are positioning for a potential rebound. However, options activity is not confirmation of a fundamental recovery.
• Neutral Sentiment: HC Wainwright and Mizuho reaffirmed neutral ratings. Their stance indicates limited conviction that the remaining pipeline currently supports a bullish investment case.
• Negative Sentiment: JPMorgan downgraded EyePoint from neutral to underweight, while Guggenheim cut its rating from buy to neutral. The downgrades reflect reduced confidence after the LUCIA setback.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet AMD clinical trials early after disappointing LUCIA results. The company is redirecting resources toward DURAVYU’s diabetic macular edema program, but the restructuring underscores the loss of a major development catalyst. Benzinga workforce and clinical-trial report
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses after the trial disclosure. The investigation adds legal and reputational risk. Levi and Korsinsky investigation notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.